Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Lumos Pharma Inc
Healthcare
P/NCAV
0.85x
Ticker
LUMO
Exchange
NASDAQ
Country
United States
Close
2.8 $
Mkt Cap
22.8M $
EV
-12.3M $
NCAV Burn Rate
55.0%
Current Ratio
5.69
Debt/Equity
0.0
EV/REV
-5.98x
EV/EBIT
0.3x
EV/FCF
0.4x
Dilution
10.0% p.A
Total Net Income
-292.4M $
Cheapness
57.0%
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average